Literature DB >> 27611917

Comparison of various scores for predicting success of chronic total occlusion percutaneous coronary intervention.

Aris Karatasakis1, Barbara A Danek1, Dimitri Karmpaliotis2, Khaldoon Alaswad3, Farouc A Jaffer4, Robert W Yeh5, Mitul Patel6, John N Bahadorani6, William L Lombardi7, R Michael Wyman8, J Aaron Grantham9, David E Kandzari10, Nicholas J Lembo10, Anthony H Doing11, Catalin Toma12, Jeffrey W Moses2, Ajay J Kirtane2, Manish A Parikh2, Ziad A Ali2, Santiago Garcia13, Pratik Kalsaria1, Judit Karacsonyi1, Aya J Alame1, Craig A Thompson14, Subhash Banerjee1, Emmanouil S Brilakis15.   

Abstract

BACKGROUND: Various scoring systems have been developed to predict the technical outcome and procedural efficiency of chronic total occlusion (CTO) percutaneous coronary intervention (PCI).
METHODS: We examined the predictive capacity of 3 CTO PCI scores (Clinical and Lesion-related [CL], Multicenter CTO registry in Japan [J-CTO] and Prospective Global Registry for the Study of Chronic Total Occlusion Intervention [PROGRESS CTO] scores) in 664 CTO PCIs performed between 2012 and 2016 at 13 US centers.
RESULTS: Technical success was 88% and the retrograde approach was utilized in 41%. Mean CL, J-CTO and PROGRESS CTO scores were 3.9±1.9, 2.6±1.2 and 1.4±1.0, respectively. All scores were inversely associated with technical success (p<0.001 for all) and had moderate discriminatory capacity (area under the curve 0.691 for the CL score, 0.682 for the J-CTO score and 0.647 for the PROGRESS CTO score [p=non-significant for pairwise comparisons]). The difference in technical success between the minimum and maximum CL score strata was the highest (32%, vs. 15% for J-CTO and 18% for PROGRESS CTO scores). All scores tended to perform better in antegrade-only procedures and correlated significantly with procedure time and fluoroscopy dose; the CL score also correlated significantly with contrast utilization.
CONCLUSIONS: CL, J-CTO and PROGRESS CTO scores perform moderately in predicting technical outcome of CTO PCI, with better performance for antegrade-only procedures. All scores correlate with procedure time and fluoroscopy dose, and the CL score also correlates with contrast utilization. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Chronic total occlusion; Complications; Outcomes; Percutaneous coronary intervention; Procedural success; Techniques

Mesh:

Year:  2016        PMID: 27611917     DOI: 10.1016/j.ijcard.2016.08.317

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  9 in total

1.  Use of sodium nitroprusside in retrograde percutaneous coronary intervention for chronic total occlusion: A case report.

Authors:  He Huang; Yao-Jun Zhang; Yong-Zhen Fan; Xi Wu; Christos V Bourantas
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

2.  Differences in patients and lesion and procedure characteristics depending on the age of the coronary chronic total occlusion.

Authors:  Krzysztof L Bryniarski; Gerald S Werner; Kambis Mashayekhi; Jarosław Wójcik; David Hildick-Smith; George Sianos; Alfredo R Galassi; Roberto Garbo; Carlo Di Mario; Kamil Fijorek; Nicolas Boudou; Nicolaus Reifart; Leszek Bryniarski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-01-21       Impact factor: 1.426

3.  The hybrid algorithm in treatment of coronary chronic total occlusions - MSWiA Lublin CTO 5-year registry.

Authors:  Drozd Jakub; Marcin Kowalski; Tomasz Wołyniak; Monika Zaręba-Giezek
Journal:  Postepy Kardiol Interwencyjnej       Date:  2020-10-02       Impact factor: 1.426

4.  Choice of CTO scores to predict procedural success in clinical practice. A comparison of 4 different CTO PCI scores in a comprehensive national registry including expert and learning CTO operators.

Authors:  Pablo Salinas; Nieves Gonzalo; Víctor H Moreno; Manuel Fuentes; Sandra Santos-Martinez; José Antonio Fernandez-Diaz; Ignacio J Amat-Santos; Francisco Bosa Ojeda; Juan Caballero Borrego; Javier Cuesta; José María de la Torre Hernández; Alejandro Diego-Nieto; Daniela Dubois; Guillermo Galeote; Javier Goicolea; Alejandro Gutiérrez; Miriam Jiménez-Fernández; Jesús Jiménez-Mazuecos; Alfonso Jurado; Javier Lacunza; Dae-Hyun Lee; María López; Fernando Lozano; Javier Martin-Moreiras; Victoria Martin-Yuste; Raúl Millán; Gema Miñana; Mohsen Mohandes; Francisco J Morales-Ponce; Julio Núñez; Soledad Ojeda; Manuel Pan; Fernando Rivero; Javier Robles; Sergio Rodríguez-Leiras; Sergio Rojas; Juan Rondán; Eva Rumiz; Manel Sabaté; Juan Sanchís; Beatriz Vaquerizo; Javier Escaned
Journal:  PLoS One       Date:  2021-04-02       Impact factor: 3.240

Review 5.  Validation of the newly introduced CASTLE Score for predicting successful CTO recanalization.

Authors:  Jan-Erik Guelker; Yoshihisa Kinoshita; Joachim Weber-Albers; Alexander Bufe; Christian Blockhaus; Kambis Mashayekhi
Journal:  Int J Cardiol Heart Vasc       Date:  2022-01-15

6.  A Novel Classification for Predicting Chronic Total Occlusion Percutaneous Coronary Intervention.

Authors:  Dongfeng Zhang; Haoran Xing; Rui Wang; Jinfan Tian; Zhiguo Ju; Lijun Zhang; Hui Chen; Yi He; Xiantao Song
Journal:  Front Cardiovasc Med       Date:  2022-02-28

Review 7.  Percutaneous Coronary Intervention in Chronic Total Occlusion.

Authors:  Luiz Fernando Ybarra; Marcelo J C Cantarelli; Viviana M G Lemke; Alexandre Schaan de Quadros
Journal:  Arq Bras Cardiol       Date:  2018-05       Impact factor: 2.000

Review 8.  Chronic Total Occlusion Percutaneous Coronary Intervention: Evidence and Controversies.

Authors:  Peter Tajti; Emmanouil S Brilakis
Journal:  J Am Heart Assoc       Date:  2018-01-12       Impact factor: 5.501

9.  Scoring System for Identification of "Survival Advantage" after Successful Percutaneous Coronary Intervention in Patients with Chronic Total Occlusion.

Authors:  Tatsuya Nakachi; Shun Kohsaka; Masahisa Yamane; Toshiya Muramatsu; Atsunori Okamura; Yoshifumi Kashima; Shunsuke Matsuno; Masami Sakurada; Yoshitane Seino; Maoto Habara
Journal:  J Clin Med       Date:  2020-05-02       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.